Innate type 1 immune response, but not IL-17 cells control tuberculosis infection.

Animals Humans Immunity, Innate Interleukin-17 Mycobacterium tuberculosis Tuberculosis
IL-1 IL-17 blockade Innate immunity Interferons Mycobacterial infection TNF

Journal

Biomedical journal
ISSN: 2320-2890
Titre abrégé: Biomed J
Pays: United States
ID NLM: 101599820

Informations de publication

Date de publication:
04 2021
Historique:
received: 28 04 2020
revised: 16 06 2020
accepted: 29 06 2020
pubmed: 17 8 2020
medline: 28 9 2021
entrez: 17 8 2020
Statut: ppublish

Résumé

The role of the innate immune response and host resistance to Mycobacterium tuberculosis infection (TB) is reviewed. Based on our data and the abundant literature, an early type 1 immune response is critical for infection control, while ILC3 and Th17 cells seem to be dispensable. Indeed, in M. tuberculosis infected mice, transcriptomic levels of Il17, Il17ra, Il22 and Il23a were not significantly modified as compared to controls, suggesting a limited role of IL-17 and IL-22 pathways in TB infection control. Neutralization of IL-17A or IL-17F did not affect infection control either. Ongoing clinical studies with IL-17 neutralizing antibodies show high efficacy in patients with psoriasis without increased incidence of TB infection or reactivation. Therefore, both experimental studies in mice and clinical trials in human patients suggest no risk of TB infection or reactivation by therapeutic IL-17 antibodies, unlike by TNF.

Identifiants

DOI: 10.1016/j.bj.2020.06.011 PMID: 32798210 PMC: PMC8178558
pubmed: 32798210
pii: S2319-4170(20)30097-4
doi: 10.1016/j.bj.2020.06.011
pmc: PMC8178558
pii:
doi:

Substances chimiques

Interleukin-17 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-171

Informations de copyright

Copyright © 2020 Chang Gung University. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest The authors declare no conflict of interest.

Références

Infect Immun. 2008 Mar;76(3):916-26
pubmed: 18212087
Sci Rep. 2013;3:1809
pubmed: 23657146
Sci Rep. 2016 Mar 02;6:22454
pubmed: 26931771
Cell Rep. 2019 May 28;27(9):2649-2664.e5
pubmed: 31141689
Am J Respir Crit Care Med. 1999 Jan;159(1):143-8
pubmed: 9872832
Immunity. 2009 Dec 18;31(6):974-85
pubmed: 20064452
Immunity. 2018 Jun 19;48(6):1091-1103
pubmed: 29924975
Immunity. 2009 Nov 20;31(5):799-810
pubmed: 19853481
Cytokine Growth Factor Rev. 2010 Dec;21(6):403-4
pubmed: 21075041
Immun Inflamm Dis. 2013 Oct;1(1):47-62
pubmed: 25400917
Science. 2015 Aug 7;349(6248):606-613
pubmed: 26160376
Microbiol Spectr. 2016 Oct;4(5):
pubmed: 27763255
Immunity. 1995 Jun;2(6):561-72
pubmed: 7540941
Nat Immunol. 2018 Aug;19(8):789-790
pubmed: 30026478
Front Immunol. 2020 Jan 15;10:3096
pubmed: 32010143
J Immunol. 2012 Jun 15;188(12):6205-15
pubmed: 22566567
Rheumatology (Oxford). 2014 Oct;53(10):1872-85
pubmed: 24821849
Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34
pubmed: 27924643
Sci Immunol. 2020 Jan 3;5(43):
pubmed: 31901072
Am J Respir Crit Care Med. 1996 Feb;153(2):799-804
pubmed: 8564135
Sci Rep. 2016 Nov 17;6:36923
pubmed: 27853279
Trends Microbiol. 2017 Nov;25(11):906-918
pubmed: 28625530
N Engl J Med. 2015 Sep 17;373(12):1179-80
pubmed: 26376149
Clin Infect Dis. 2006 Sep 15;43(6):717-22
pubmed: 16912945
Science. 2019 Mar 8;363(6431):
pubmed: 30846571
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):23-28
pubmed: 31662735
Annu Rev Immunol. 2001;19:93-129
pubmed: 11244032
Respir Med. 2009 May;103(5):661-9
pubmed: 19201589
J Innate Immun. 2018;10(3):239-252
pubmed: 29791904
Immunity. 2011 Dec 23;35(6):1023-34
pubmed: 22195750
J Comp Eff Res. 2018 Nov;7(11):1107-1123
pubmed: 30230361
N Engl J Med. 2001 Oct 11;345(15):1098-104
pubmed: 11596589
Infect Immun. 2001 Jul;69(7):4195-201
pubmed: 11401954
Nat Commun. 2018 Dec 6;9(1):5226
pubmed: 30523277
F1000Res. 2017 May 23;6:741
pubmed: 28713557
Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S189-93
pubmed: 15983898
Curr Dir Autoimmun. 2010;11:157-79
pubmed: 20173394
Front Immunol. 2019 Sep 11;10:2139
pubmed: 31572365
Nat Rev Immunol. 2012 Jul 13;12(8):581-91
pubmed: 22790178
Trends Immunol. 2019 Aug;40(8):719-734
pubmed: 31262653
Front Immunol. 2018 Apr 10;9:709
pubmed: 29692778
Annu Rev Pathol. 2012;7:353-84
pubmed: 22054143
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1449-1456
pubmed: 32012384
J Immunol. 2003 Sep 15;171(6):3110-8
pubmed: 12960337
Nat Immunol. 2020 Jan;21(1):17-29
pubmed: 31819255
Ann Rheum Dis. 2018 Apr;77(4):523-532
pubmed: 29275332
Immunity. 2015 Dec 15;43(6):1125-36
pubmed: 26682985
J Immunol. 2004 Sep 1;173(5):3287-96
pubmed: 15322191
Semin Immunol. 2014 Dec;26(6):552-8
pubmed: 25444549
Nature. 2019 Jun;570(7762):528-532
pubmed: 31168092
Microbes Infect. 2007 Apr;9(5):623-8
pubmed: 17409008
Clin Immunol. 2000 Mar;94(3):192-9
pubmed: 10692238
J Infect Dis. 2020 Apr 7;221(9):1554-1563
pubmed: 31805183
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7958-63
pubmed: 11438742

Auteurs

Noria Segueni (N)

Molecular and Experimental Immunology and Neurogenetics, UMR 7355, INEM, CNRS-University of Orleans, Orleans, France.

Muazzam Jacobs (M)

Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa; National Health Laboratory Service, Johannesburg, South Africa; Immunology of Infectious Disease Research Unit, University of Cape Town, South Africa.

Bernhard Ryffel (B)

Molecular and Experimental Immunology and Neurogenetics, UMR 7355, INEM, CNRS-University of Orleans, Orleans, France. Electronic address: bryffel@cnrs-orleans.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Innate type 1 immune response, but not IL-17...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Innate type 1 immune response, but not IL-17...
Recherchemedicale.com › Phénomènes du système immunitaire › Immunité › Immunité innée › Innate type 1 immune response, but not IL-17...
Recherchemedicale.com › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-17 › Innate type 1 immune response, but not IL-17...
Recherchemedicale.com › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Innate type 1 immune response, but not IL-17...
Recherchemedicale.com › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Innate type 1 immune response, but not IL-17...